A Review on Optizorb Technology

Author(s)

Firdous, A., Khaleq, M.K., Ahmed, S.

Author's Affiliation

Abstract

The article here under emphasizes on how absorption of certain drug can be improved. A novel concept implies when tablets were offered ease of oral administration and increases patient compliance. Technology which allows the tablet to start disintegrating in as little as 5 minutes is called Optizorb Technology. Optizorb disintegration technology is five times faster and shows action more quickly. It gets easily dispersed in stomach and work faster, relief faster. Optizorb technology is based on the use of super-disintegrant such as Alginic acid and Calcium Carbonate that makes it act within five minutes. According to the International Association for the study of pain is defined as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage.” Panadol with Optizorb Technology is a Paracetamol based analgesic, using a new disintegrate technology that provides Fast, Suitable, effective relief of Pain and discomfort associated with headache and Migraine. However, Sometimes Standard Paracetamol tablets slowly dissolve and absorb, and can sometimes takes a long time to impart its effects. Panadol with Optizorb technology also relieves fever. Panadol with Optizorb technology contain 3 stages stage.1 disintegration stage – 2. Dissolution stage- 3. Absorption  dissolves quickly (in the stomach)  due to Super-disintegration which causes the tablet to swell even more, and Speeds up the break up process For pain relief a person can Start to feel in as little as 15 minutes. Panadol with Optizorb technology can still be used by a broad range of people including people with stomach ulcers and breastfeeding mothers.

Keywords

Pain, Optizorb Technology, Panadol, Super Disintegrate, Stomach ulcers, Quick absorption

Cite This Article

Firdous, A., Khaleq, M.K., Ahmed, S. (2016). A Review on Optizorb Technology, International Journal for Pharmaceutical Research Scholars (IJPRS), 5(4), 113-127.